B cell targeted therapies
What are B cell targeted therapies? RTX (Rituxan): chimeric mouse–human IgG1κ monoclonal antibody directed against extracellular domain of CD20 antigen on B cells. B cells are eliminated by complement-mediated lysis, antibody-dependent cell-mediated cytotoxicity, or apoptosis. All peripheral B cells are eliminated within days. Patients who fail to deplete their B cells respond less well. Notably, Ig …